Thymosin Alpha-1 10mg — Vial Spec, Reconstitution Math & COA

Overview of Thymosin Alpha-1 10mg Specifications and Catalog Availability

Thymosin Alpha-1 (TA1) is an acidic 28-amino acid polypeptide originally isolated from bovine thymus tissue fraction 5, now produced synthetically via solid-phase peptide synthesis (SPPS) to guarantee structural purity and batch consistency. In laboratory research, a 10mg vial format represents a high-density, lyophilized cake intended for high-volume liquid handling systems or longitudinal experimental series. Having 10,000 micrograms of active peptide in a single glass container reduces the requirement for frequent vial opening, minimizing potential exposure to environmental moisture and atmospheric oxidation during multi-plate transfers.

While some custom research protocols specifically specify a 10mg fill mass, laboratory inventory requirements often favor smaller aliquots to prevent repeat freeze-thaw degradation. For this reason, PX1 Research maintains immediate inventory of the Thymosin Alpha-1 5mg vial, which offers optimal stability for standard laboratory workflows while maintaining strict cost control. Researchers requiring larger bulk quantities or specific single-fill masses beyond our active product line can explore our wholesale program to request custom lot sizes, enterprise pricing, and synchronized delivery schedules directly from our USA manufacturing facilities.

Molecular Identity and Chemical Structure of Synthetic Thymosin Alpha-1

Synthetic Thymosin Alpha-1 possesses the empirical formula C129H215N33O55 and a precise molecular weight of approximately 3,108.3 Da. Structurally, the molecule features an N-terminal acetylation (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH), which confers enhanced enzymatic resistance compared to non-acetylated peptide fragments in aqueous buffer systems. The peptide is synthesized under strict Good Manufacturing Practice (GMP) compliance within ISO 17025 accredited facilities, ensuring that every lot exhibits correct primary sequence alignment without truncations or sequence deletions.

In its native state, Thymosin Alpha-1 operates as an endogenous peptide mediator involved in cell-mediated immune responses. In preclinical models, researchers utilize synthetic TA1 to evaluate receptor-binding kinetics, toll-like receptor (TLR) signal transductive pathways, and T-cell maturation cascades. When inspecting our full catalog of peptides, investigators can compare sequence properties, solubility metrics, and physical state attributes across our entire research inventory.

Preclinical Research Context and Proposed Receptor Pathways

Preclinical studies suggest that Thymosin Alpha-1 acts as a potent immunomodulatory peptide through interaction with innate immune system pattern recognition receptors, particularly Toll-like Receptor 4 (TLR4) and Toll-like Receptor 7 (TLR7). In vitro data indicate that exposure to TA1 upregulates the activity of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling cascades, promoting the downstream expression of key cytokines such as interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon-gamma (IFN-γ). These biochemical events are actively studied to determine how peptide signaling drives the differentiation of naive CD4+ helper T-cells into functional Th1 phenotypes.

Furthermore, animal models evaluating viral challenge and oncology pathways demonstrate that Thymosin Alpha-1 administration induces upregulation of major histocompatibility complex (MHC) Class I expression on antigen-presenting cells. Research models also report an increase in natural killer (NK) cell cytotoxicity and enhanced dendritic cell maturation upon peptide exposure. Because these intracellular mechanisms operate via specific receptor-ligand stoichiometry, maintaining absolute concentration precision during volumetric reconstitution is mandatory for obtaining reproducible scientific data.

Reconstitution Math for a 10mg Thymosin Alpha-1 Vial

Accurate reconstitution is the foundation of reliable quantitative research. To convert a 10mg (10,000 µg) lyophilized cake of Thymosin Alpha-1 into a usable liquid stock, researchers must select an appropriate diluent, such as Sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl), based on experimental requirements. Applying the formula Concentration (c) = Mass (m) / Volume (v), the resulting stock concentration depends directly on the volume of diluent injected into the vial.

Below are the standardized concentration calculations for common diluent volumes added to a 10mg Thymosin Alpha-1 vial:

• 1.0 mL Diluent Addition: Yields a concentration of 10.0 mg/mL (10,000 µg/mL). A 10 µL pipette delivery delivers exactly 100 µg of active research compound.

• 2.0 mL Diluent Addition: Yields a concentration of 5.0 mg/mL (5,000 µg/mL). A 10 µL pipette delivery delivers exactly 50 µg of active research compound.

• 3.0 mL Diluent Addition: Yields a concentration of 3.33 mg/mL (3,333 µg/mL). A 10 µL pipette delivery delivers approximately 33.3 µg of active research compound.

• 5.0 mL Diluent Addition: Yields a concentration of 2.0 mg/mL (2,000 µg/mL). A 10 µL pipette delivery delivers exactly 20 µg of active research compound.

For complex target concentrations or variable multi-diluent formulations, research personnel should utilize our interactive reconstitution calculator to verify volumetric pipetting inputs prior to liquid transfer.

Step-by-Step Reconstitution Protocol and Aliquot Planning

When executing reconstitution in the laboratory, strict aseptic technique must be observed within a certified laminar flow hood. Allow the 10mg Thymosin Alpha-1 vial to equilibrate to room temperature (20°C to 25°C) before reconstitution to prevent ambient water vapor condensation upon opening. Disinfect the rubber septum using a 70% isopropyl alcohol swab and allow it to air-dry completely. Using a sterile precision syringe, draw the calculated volume of diluent and slowly direct the stream against the glass inner wall of the vial. Avoid spraying diluent directly onto the lyophilized cake to prevent shear stress and foaming.

Gently swirl the vial in a circular motion until the cake is fully dissolved into a clear, colorless liquid. Never vortex or vigorously shake peptide solutions, as mechanical agitation can induce protein denaturation and insoluble aggregate formation. If the protocol requires low working concentrations over an extended timeline, immediately divide the reconstituted liquid into single-use, polypropylene micro-centrifuge tubes (aliquots). Aliquoting eliminates the need for repeated freeze-thaw cycles, preserving peptide structural integrity and preventing enzymatic cleavage or chemical hydrolysis.

Storage Parameters and Stability Guidelines

Lyophilized Thymosin Alpha-1 exhibits robust long-term stability when stored under controlled environmental conditions. Sealed, dry vials stored at -20°C remain stable for up to 24 months, while storage at -80°C extends shelf life further for specialized biobank archives. Lyophilized vials may be stored temporarily at 2°C to 8°C for short durations during transit or immediate assay setup, provided humidity levels are controlled.

Once reconstituted into aqueous liquid stock, the working solution should be stored at 2°C to 8°C if it is to be utilized within 7 to 14 days (assuming bacteriostatic diluent was selected). If long-term aqueous storage is required, aliquoted solutions must be stored at -20°C or -80°C. Repeated freezing and thawing of reconstituted Thymosin Alpha-1 must be avoided, as localized freeze-concentration effects cause localized pH shifts and ice crystal formation that alter peptide secondary structure. For detailed storage guidelines on related compounds, visit our centralized research library.

Analytical Quality Control: COA, HPLC, MS, and Endotoxin Testing

At PX1 Research, analytical rigor is fundamental to ensuring verifiable scientific outcomes. Every manufacturing lot of Thymosin Alpha-1 undergoes comprehensive analytical testing before batch release. Purity is validated using High-Performance Liquid Chromatography (HPLC), which confirms that the active peptide peak represents ≥98.0% of total integrated UV absorption at 214 nm. Mass Spectrometry (MS) analysis is simultaneously performed to verify the exact molecular mass (3,108.3 Da) and rule out incorrect amino acid insertion or sequence truncation.

Because Thymosin Alpha-1 is frequently utilized in sensitive cell culture models and animal research, controlling for bacterial endotoxins is vital. Endotoxin presence can trigger unintended immune responses in experimental models, confounding data analysis. Every lot is subjected to Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels fall strictly below standard research limits (<0.01 EU/µg). Researchers can instantly download and verify lot-matched analytical documentation directly through our dedicated COA lookup portal.

Comparative Analysis: Thymosin Alpha-1 vs. Related Immunomodulatory Research Compounds

In preclinical host-defense and cell-signaling research, investigators frequently evaluate Thymosin Alpha-1 alongside other peptide signaling agents. Understanding the operational differences among these molecules enables precise compound selection for specific experimental pathways:

1. Thymosin Alpha-1: Focuses primarily on adaptive immune system modulation, specifically promoting T-cell progenitor maturation, MHC Class I expression, and balanced Th1 cytokine output.

2. Thymosin Beta-4: Acts predominantly as an actin-sequestering protein fragment, regulating cell motility, tissue remodeling, angiogenesis, and focal adhesion dynamics rather than direct T-cell maturation cascades.

3. LL-37: An amphipathic alpha-helical antimicrobial host defense peptide that exerts direct membrane-disrupting activity against pathogens while modulating local innate inflammatory responses via formyl peptide receptors.

While all three compounds are categorized as host-response modifiers in preclinical literature, their molecular targets and downstream intracellular pathways differ significantly. Combining or comparing these agents in vitro requires careful titration to account for distinct receptor-binding affinities.

Selecting the Optimal Fill Size: 5mg vs. 10mg Vials for Laboratory Efficiency

Choosing between a 5mg vial and a 10mg vial depends on experimental design, assay volume requirements, and inventory turnover rate. A 10mg format provides a cost-effective bulk solution for automated liquid handling platforms, high-concentration stock preparation, or extensive animal cohort studies where large volumes of reconstituted peptide are consumed rapidly.

Conversely, laboratories performing periodic, low-volume, or single-well assays often benefit from smaller unit sizes like the Thymosin Alpha-1 5mg format. Utilizing 5mg vials limits the amount of time reconstituted solution remains in liquid storage, mitigating potential degradation pathways such as deamidation or methionine oxidation. Institutional buyers evaluating bulk procurement for institutional labs can review flexible supply arrangements through our wholesale service to match exact research timelines.